Mineralys Therapeutics (MLYS) Scheduled to Post Earnings on Tuesday

Mineralys Therapeutics (NASDAQ:MLYS) is set to issue its quarterly earnings data after the market closes on Tuesday, August 13th. Analysts expect the company to announce earnings of ($0.73) per share for the quarter. Investors that are interested in registering for the company’s conference call can do so using this link.

Mineralys Therapeutics (NASDAQ:MLYS) last announced its quarterly earnings results on Thursday, May 9th. The company reported ($0.70) earnings per share for the quarter, missing the consensus estimate of ($0.68) by ($0.02). On average, analysts expect Mineralys Therapeutics to post $-3 EPS for the current fiscal year and $-3 EPS for the next fiscal year.

Mineralys Therapeutics Price Performance

MLYS stock traded up $0.03 during mid-day trading on Tuesday, reaching $11.19. 81,063 shares of the company traded hands, compared to its average volume of 181,685. The company has a fifty day moving average price of $12.74 and a 200-day moving average price of $12.90. Mineralys Therapeutics has a 52-week low of $5.85 and a 52-week high of $16.91. The company has a market capitalization of $555.58 million, a P/E ratio of -5.08 and a beta of 1.93.

Analyst Ratings Changes

Separately, HC Wainwright initiated coverage on Mineralys Therapeutics in a report on Wednesday, July 10th. They issued a “buy” rating and a $30.00 price target on the stock.

Insider Buying and Selling at Mineralys Therapeutics

In other news, CEO Jon Congleton sold 16,607 shares of the stock in a transaction dated Wednesday, June 12th. The stock was sold at an average price of $12.77, for a total transaction of $212,071.39. Following the transaction, the chief executive officer now directly owns 1,032,461 shares in the company, valued at approximately $13,184,526.97. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. In other news, Director Brian Taylor Slingsby sold 550,000 shares of Mineralys Therapeutics stock in a transaction dated Wednesday, July 24th. The stock was sold at an average price of $13.05, for a total value of $7,177,500.00. Following the transaction, the director now owns 8,644,579 shares in the company, valued at $112,811,755.95. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Also, CEO Jon Congleton sold 16,607 shares of the stock in a transaction dated Wednesday, June 12th. The shares were sold at an average price of $12.77, for a total value of $212,071.39. Following the sale, the chief executive officer now owns 1,032,461 shares of the company’s stock, valued at $13,184,526.97. The disclosure for this sale can be found here. Insiders have sold 706,779 shares of company stock worth $9,206,318 over the last 90 days. Corporate insiders own 33.24% of the company’s stock.

About Mineralys Therapeutics

Mineralys Therapeutics, Inc, a clinical-stage biopharmaceutical company that develops therapies for the treatment of hypertension and chronic kidney diseases. It clinical-stage product candidate is lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of cardiorenal conditions affected by abnormally elevated aldosterone.